Eli Lilly, Novo Nordisk

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale shift of injectable drugs that treat obesity,
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and currently trading at $773.28. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
The Next Web21h
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
The Washington Post on MSN10d
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...